+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer



Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer



Clinical Cancer Research 6(10): 3944-3948



This prospective study was performed to assess the impact of matrix metalloproteinase (MMP) 2 expression on the clinical course of patients with operable non-small cell lung cancer (NSCLC). Specimens of 193 consecutive patients with completely resected NSCLC were examined for MMP-2 expression by immunohistochemical staining with a polyclonal antibody. Homogeneous immunostaining of cancer cells was considered positive and heterogeneous, or no staining was considered negative concerning overexpression of MMP-2. Four specimens were excluded from further analyses because of unspecific staining. The median follow-up period was 71.5 months (range, 12-120 months). Overexpression of MMP-2 was observed in 64 (33.9%) of 189 patients and did not correlate with clinicopathoiogical parameters. In patients without lymph node involvement (pN0 stage) MMP-2 overexpression was an independent prognostic parameter for unfavorable outcome: Log-rank analysis showed a significant association of MMP-2 overexpression with shortened cancer-related survival (P = 0.04) and disease-free survival (P = 0.03). Multivariate regression analysis confirmed MMP-2 overexpression as predictor of shortened cancer-related survival in NSCLC without lymph node involvement (P = 0.005, relative risk, 2.6). The present study revealed that MMP-2 overexpression predicts a poor prognosis in early-stage NSCLC. Therefore, it might be worth investigating the role of MMP inhibitors as adjuvant therapeutic agents in NSCLC.

(PDF emailed within 1 workday: $29.90)

Accession: 046897040

Download citation: RISBibTeXText

PMID: 11051242


Related references

Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histology and Histopathology 23(6): 693-700, 2008

Mortalin overexpression predicts poor prognosis in early stage of non-small cell lung cancer. Tumour Biology 39(3): 1010428317695918, 2017

Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer. European Journal of Histochemistry 56(4): E46, 2013

Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer. Clinical Cancer Research 8(4): 1152-1156, 2002

Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respiratory Medicine 98(2): 173-177, 2004

Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. Lung Cancer 58(3): 384-391, 2007

Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer. Clinical Cancer Research 12(18): 5448-5453, 2006

Metallothionein 1F and 2A overexpression predicts poor outcome of non-small cell lung cancer patients. Experimental and Molecular Pathology 94(1): 301-308, 2013

High expression of a disintegrin and metalloproteinase-9 predicts a shortened survival time in completely resected stage I non-small cell lung cancer. Oncology Letters 5(5): 1461-1466, 2013

Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. American Heart Journal 150(3): 484-487, 2005

CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer. Journal of Thoracic Oncology 6(7): 1169-1178, 2011

Overexpression of astrocyte-elevated gene-1 is closely correlated with poor prognosis in human non-small cell lung cancer and mediates its metastasis through up-regulation of matrix metalloproteinase-9 expression. Human Pathology 43(7): 1051-1060, 2012

Overexpression of small GTPases directly correlates with expression of δ-catenin and their coexpression predicts a poor clinical outcome in nonsmall cell lung cancer. Molecular Carcinogenesis 52(5): 338-347, 2013

Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Research 60(15): 4000-4004, 2000

Arterial invasion predicts early mortality in stage I non-small cell lung cancer. Annals of Thoracic Surgery 78(5): 1748-1753, 2004